Real estate
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
In June 2018, Kilroy said it plans to develop, over multiple phases, a state-of-the-art laboratory and office complex that will eventually encompass 11 buildings spread across a nearly 40-acre waterfront site in the Bay Area.
Investments from Merck KGaA, Beacon Pharmaceuticals and Genomenon will provide new jobs for local economies.
Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.
According to a real estate analysis, the per-square-foot costs in Kendall Square increased $18 in 2018.
Promore Pharma AB announced that the company is making adjustments to the manufacturing chain of the investigational medicinal product for the company’s clinical phase III study, PSHU03, with PXL01 for prevention of adhesions following tendon repair surgery.
Auris Medical Holding AG announced its intention to relocate the Company’s domicile from Zug, Switzerland to Hamilton, Bermuda.
Could Denmark become the site of Europe’s answer to Silicon Valley? The Danish government is banking on it. If it comes to fruition, the project could provide up to 12,000 life science jobs.
The Almac Group, a CDMO serving the pharmaceutical and biotech sectors globally, is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities.
SQZ Biotech is on a roll. Months after securing $72 million in a Series C financing round and expanding a developmental agreement with pharma giant Roche worth up to $1 billion, the company is now expanding its footprint in Watertown, Mass.
PRESS RELEASES